Seeking Alpha downgrades Regeneron stock to Hold

Published on 10/05/2026 at 15:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 17.00 percent to USD 4.29 billion. Regeneron stock costs EUR 655.15 on October 5, 2026 after EUR 653.35.

Architektur-Render eines modernen Glas- und Stahl-Forschungsgebäudes mit Vorplatz — Regeneron Pharma US75886F1075 zeigt ein architektonisches 3D-Render eines modernen Glas-Forschungsgebäudes mit gepflegten Grünflächen davor, Illustration mit AI erstellt.

Regeneron (ISIN US75886F1075) was trading at EUR 655.15 at Lang & Schwarz on October 5, 2026 at 3:06 p.m. CEST, versus a prior close of EUR 653.35. On October 4, 2026, Seeking Alpha reported that Regeneron had been downgraded to Hold, while new clinical data added a second business development angle.

Hold rating meets trial data

The downgrade article described the stock as priced near the author's discounted cash flow value at USD 735.00 and identified Dupixent growth, Eylea durability and the research pipeline as the main supports for the company.

That assessment arrived after Regeneron's October 1, 2026 announcement of Phase 2 COURAGE results. Finanznachrichten reported that trevogrumab preserved 68.90 percent of thigh muscle volume at 52 weeks in the 75 milligram combination arm, compared with semaglutide alone.

Second-quarter revenue reached USD 4.29 billion

Regeneron's second-quarter 2026 total revenue rose 17.00 percent year over year to USD 4.29 billion, according to RTT News. The comparison was USD 3.68 billion in the second quarter of 2025.

GAAP net income was USD 1.30 billion in the second quarter of 2026, versus USD 1.39 billion a year earlier, while diluted GAAP earnings per share were USD 12.23 compared with USD 12.81. The figures show that revenue growth did not translate into higher GAAP profit in the reported quarter.

Regeneron's commercial mix remains central to the debate. In the second quarter of 2026, Eylea HD U.S. sales reached USD 596.00 million, up 52.00 percent year over year, while Dupixent global net product sales reached USD 6.00 billion, up 38.00 percent on a constant-currency basis, as reported in the company's earnings call carried by Fortune.

Third-quarter results are due October 30

Regeneron is scheduled to report its third-quarter 2026 financial and operating results on October 30, 2026, before the U.S. financial markets open, according to RTT News. That date gives the market a defined test for whether the Sanofi development-balance repayment improves collaboration profits as management expects.

For investors, the key tension is visible in the numbers: the pipeline is producing new clinical evidence, but the second-quarter GAAP earnings comparison was lower despite 17.00 percent revenue growth.

Regeneron stock stays below its yearly high

Regeneron was trading at EUR 655.15 at Lang & Schwarz on October 5, 2026 at 3:06 p.m. CEST, up 0.28 percent versus the EUR 653.35 prior close at Lang & Schwarz on October 2, 2026. The primary Nasdaq listing had a USD 541.00 to USD 859.34 52-week range and a USD 75.7 billion market capitalization as of October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.